Tianjin, China

Yan Zeng

This inventor holds 1 USPTO granted patent. Top assignee: Chinese Academy of Sciences. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yan Zeng. Retrieved from https://idiyas.com/inventor/yan-zeng-8mk8iaq2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yan Zeng: Innovator in Enzyme Engineering

Introduction

Yan Zeng is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of enzyme engineering, particularly through his innovative work on allulose 3-epimerase mutants. His research has the potential to impact various industries, including food and biotechnology.

Latest Patents

Yan Zeng holds a patent for "Allulose 3-epimerase mutant, engineered bacterium expressing same, and immobilized enzyme and immobilization method thereof." This patent showcases his expertise in developing engineered enzymes that can be utilized in various applications.

Career Highlights

Zeng is affiliated with the Chinese Academy of Sciences, where he conducts his research and development. His work has garnered attention for its innovative approach to enzyme engineering, contributing to advancements in the field.

Collaborations

Yan Zeng collaborates with Yueming Zhu, a talented researcher in the same field. Their partnership enhances the scope of their research and fosters innovation in enzyme applications.

Conclusion

Yan Zeng's contributions to enzyme engineering exemplify the spirit of innovation in scientific research. His work continues to pave the way for advancements in biotechnology and related fields.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…